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We report a case of squamous differentiated prostate carcinoma that developed after combination
endocrine therapy for adenocarcinoma of the prostate. The patient was a 68-year-old man who visited our
hospital with microscopic hematuria. His serum prostate-specific antigen (PSA) level was 7. 06 ng/ml.
Transperineal needle biopsy was performed and histological examinations indicated moderately
differentiated adenocarcinoma with a Gleason score of 4＋4＝8. Computed tomography showed swelling of
left external iliac lymph node. The clinical stage was T3aN1M0. Six weeks after combination endocrine
therapy using goserelin acetate and bicalutamide, the patient underwent radical prostatectomy and bilateral
pelvic lymphadenectomy. Histopathological examination of the surgical specimen demonstrated squamous
cell carcinoma of the prostate with very small areas of adenocarcinoma. The treatment measure was
changed from endocrine therapy to combination chemotherapy consisting of docetaxel, cisplatin, and 5-
FU. Eighteen month has passed after the surgery without any evidence of distant metastasis.
(Hinyokika Kiyo 58 : 457-460, 2012)













現病歴，経過 : 2009年 3月，顕微鏡的血尿を主訴に




differentiated，Gleason Score : 4＋4＝8) と診断した
(Fig. 1）．顕微鏡的血尿の精査のため膀胱尿道内視鏡
泌58,08,15-1
Fig. 1. Microscopic findings of a biopsy specimen of
the prostate before combination endocrine
therapy showed moderately differentiated
adenocarcinoma with a Gleason score of 4＋
4＝8.
泌尿紀要 58 : 457-460，2012年 457
検査を行ったところ前立腺部尿道に一部隆起性病変を






た． 6 週間の術前内分泌治療 (goserelin acetate，

















Fig. 2. Microscopic findings of the surgical specimen after combination endocrine therapy for adenocarcinoma
showed squamous cell carcinoma (A-circles, B) (HE×200). Immunohistochemistry revealed that the
tumor cells were positive for 34-beta E12 (C).
の代表抗体）および SCC は陰性であった．HE 所見
と免疫染色の結果により腺癌であることを確認し，生
検組織での扁平上皮癌の存在は否定された．全摘組織
でも同様に免疫染色を行い，HE 所見 (Fig. 2B) で扁
平上皮癌と診断した腫瘍細胞について 34-beta E12








SCC 抗原は術後 2週目で 1.6 ng/ml（基準値 1.5 ng/
ml 以下）と軽度上昇を認め，腫瘍残存の可能性を考
慮して術後化学治療を追加した．頭頸部扁平上皮癌の
治療を参考にして TPF (docetaxel ; 75 mg/m2 day 1，
cisplatin ; 75 mg/m2 day 1，5-FU ; 750 mg/m2 day 1∼5)
療法を術後計 5コース行い SCC の陰性化を得た．現
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Table 1. Cases of prostate carcinoma with squamous differentiation after endocrine therapy in Japan
報告年度 報告者 年齢 治療前 PSA (ng/ml) GS 病期 ○1内分泌治療内容 ○2内分泌治療期間 転帰
2000 門間2) 76 604 不明 D2
○1 Castration，diethylstilbestrol，flutamide，UFT
○2 6年間 死亡
2001 折笠3) 77 16 不明 B1
○1 LH-RH，antiandrogen
○2 2年 5カ月間 死亡
2008 宮本4) 76 100 4＋5＝9 不明
○1 LH-RH，bicalutamide
○2 5年 1カ月間 不明











目であった (Table 1)2~4)．Braslis らは stage D1 の腺癌







































独 : 8例，内分泌治療および放射線治療併用 : 1例）
に内分泌治療施行歴があった．使用薬剤は leuprolide
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